trending Market Intelligence /marketintelligence/en/news-insights/trending/thM-9tjntseRkiMy1IkKIg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

UCB SA's psoriatic arthritis drug bimekizumab significantly improved joint and skin symptoms in a phase 2b trial.

Psoriatic arthritis is an inflammatory condition affecting the joints and skin.

The study met its primary goal with up to 46% of psoriatic arthritis patients who received the treatment seeing at least 50% improvement in joint symptoms after 12 weeks, compared with 7% of patients on placebo.

Among patients with skin lesions, 65% of those who received the drug experienced at least 90% skin clearance at week 12, compared with 7% who received placebo.

Bimekizumab has also demonstrated its efficacy in treating ankylosing spondylitis, a type of arthritis that mainly affects the spine. In a phase 2b study, 47% of patients receiving bimekizumab achieved at least 40% improvement in disease symptoms, compared to 13% receiving placebo after 12 weeks.